Key Takeaways
- Researchers have developed a new imaging technique, ASA-PD, to detect alpha-synuclein oligomers in human brain tissue.
- This advancement could enhance understanding of Parkinson’s disease mechanisms and aid in finding early diagnostics and treatments.
- An increase in global Parkinson’s cases is expected, projected to reach 25 million by 2050, with no current therapy to halt its progression.
New Imaging Technique Unveils Parkinson’s Disease Oligomers
Researchers from the University of Cambridge, UCL, the Francis Crick Institute, and Polytechnique Montréal have pioneered an imaging method to visualize alpha-synuclein oligomers in human brain tissue, previously undetectable. This breakthrough, reported in the journal Nature Biomedical Engineering, could provide significant insights into how Parkinson’s disease spreads in the brain and lead to improved diagnostic and therapeutic strategies.
Currently, around 166,000 individuals in the UK are diagnosed with Parkinson’s disease, with global projections suggesting this number could double to 25 million by 2050. While existing medications alleviate some symptoms like tremors and rigidity, there are no treatments available that can slow or stop the disease’s progress.
Traditionally, doctors have identified Parkinson’s disease through the presence of Lewy bodies, large protein aggregates associated with the condition. However, it is now believed that smaller, earlier-forming oligomers could trigger detrimental effects on brain cells. Up until now, these oligomers were difficult to detect due to their minuscule size, measuring only a few nanometers.
Professor Steven Lee from Cambridge’s Yusuf Hamied Department of Chemistry noted, “Lewy bodies are the hallmark of Parkinson’s, but they essentially tell you where the disease has been, not where it is right now. Observing Parkinson’s at its earliest stages could provide vital insights into its development.”
The newly developed Advanced Sensing of Aggregates for Parkinson’s Disease (ASA-PD) technique employs ultra-sensitive fluorescence microscopy that enables the detection and analysis of millions of oligomers found in post-mortem brain tissue samples. Due to the weak signal from these tiny oligomers, ASA-PD optimizes the detection process by enhancing the signal while reducing background noise, allowing for the observation of individual alpha-synuclein oligomers.
For the first time, researchers have successfully examined oligomers in human brain tissue at this scale, likening the achievement to “seeing stars in broad daylight.” The team compared brain samples from individuals with Parkinson’s disease to those from similar-aged, healthy individuals. While oligomers were found in both, the oligomers in Parkinson’s brains were larger, brighter, and more abundant, indicating a correlation with the disease’s progression.
A noteworthy finding was the existence of a subclass of oligomers exclusive to Parkinson’s patients, potentially serving as early indicators of the disease many years prior to symptom onset.
Professor Lucien Weiss from Polytechnique Montréal remarked on the significance of the findings, mentioning that this new method provides an extensive map of protein changes within the brain, offering potential for applications in other neurodegenerative diseases such as Alzheimer’s and Huntington’s.
Professor Sonia Gandhi from The Francis Crick Institute emphasized the complexities of studying human disease, stating that understanding requires direct investigation of the human brain. The breakthrough at hand aims to unravel the formation and impact of protein clusters in the brain environment associated with disease progression.
The content above is a summary. For more details, see the source article.